Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invent Medic Sweden AB’s product Efemia bladder support will be listed on the 15[th] of October for reimbursement in Germany.

Invent Medic Sweden AB announces that its distributor Arteriomed GmbH has received information from The National Association of Health Insurance Funds GKV that it will, from October 15 2020, include Invent Medic’s first product Efemia bladder support in the list of medicinal products of the statutory health insurance companies.By inclusion on the statutory list of medicinal products, Efemia bladder support will be listed to the pharmacies in Germany as an aid eligible for reimbursement, according to the Aids Directive of the Federal Joint Committee. - We are in active discussions with

Nustay files for bankruptcy following serious challenges of the COVID-19 crisis

Nustay A/S (“Nustay”) has today announced that as a result of the COVID-19 crisis, it will be filing for bankruptcy. The company has experienced a very significant drop in sales volume due to the continuing global travel restrictions - with sales at 5% of the volume of January and February 2020. This continued industry-wide uncertainty has also made meant that the company has been unable to secure sufficient funding to continue operations.COVID-19 crisis has continued to present difficult challenges As a result of the continuing global travel restrictions, Nustay’s Board of Directors

SOTKAMO SILVER AB HAS PUBLISHED THE ANNUAL REPORT FOR 2020

Sotkamo Silvers AB´s Annual Report for 2020 is available on the Company’s web page: https://www.silver.fi/en/investors/financial-reports/annual-reports Stockholm March 31, 2021 Sotkamo Silver AB Erkki Kuronen, CEO Contact person Erkki Kuronen, CEO, tel. +358 50 599 3539 This information is information that Sotkamo Silver AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above on March 31, 2021, at XX:XX CET. The

Scandion Oncology announces that it has been selected for the final round of MATWIN presentations

Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has been selected to present the company for the MATWIN Board and investors.The MATWIN program is an activity installed by the French Government as a collaboration with Pharma companies, investors and patient advocacy groups to accelerate development of future oncology treatments. Projects selected in the MATWIN process are characterized by high quality science and a ground-breaking potential to make a difference for cancer patients. In the selection process candidate projects are on the one hand scrutinized and

Teleste has signed an agreement to sell its services business in Germany to Circet

TELESTE CORPORATION   INSIDER INFORMATION   2 October 2020 AT 22:00 EET TELESTE HAS SIGNED AN AGREEMENT TO SELL ITS SERVICES BUSINESS IN GERMANY TO CIRCET  Teleste has signed an agreement to sell its services business in Germany to Circet Deutschland GmbH, a company of the Circet Group. Circet is the leading European telecom network service provider with activities in France, Ireland, the UK, Spain, Germany and Morocco. Circet provides a wide range of construction, installation and maintenance services for fixed and mobile networks. In 2019, the revenue of Circet was EUR 1.4 billion

Communique from the Extraordinary General Meeting of Scandion Oncology A/S

On Thursday 1 October 2020, the Extraordinary General Meeting of Scandion Oncology A/S was held. Below follows a summary of the established decisions. All decisions were taken with the required majority and in accordance with the notice of the extraordinary general meeting.Establishment of an incentive program by issuance of warrants to the board of directors The general meeting decided that Scandion Oncology A/S will establish an incentive program by issuance of up to 214,338 warrants to the board of directors of Scandion Oncology A/S to be distributed as follows: (i) Chairman: 71,

Major shareholder announcement – Société Générale S.A.’s holding above 5 percent as at 30 September 2020

Vestas Wind Systems A/S, Aarhus, 02 October 2020Company announcement No. 30/2020   Major shareholder announcement – Société Générale S.A.’s holding above 5 percent as at 30 September 2020 Pursuant to Section 30 of the Danish Capital Markets Act, Vestas Wind Systems A/S hereby informs that the company has been notified on 2 October 2020 that Société Générale S.A., 29 Boulevard Haussmann, 75009 Paris, France, on 30 September 2020 had the following holding of Vestas shares and financial instruments – corresponding to a position of 5.76 percent of the total share capital in Vestas

The subscription price for the warrants of series 2020:1 has been set to SEK 12.00 and the exercise period begins on Monday 5 October 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, BE SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES During June-July 2020, Eurobattery Minerals AB (publ) (NGM Nordic SME: "BAT"; "the Company") carried out a rights issue of units, consisting of shares and warrants of series 2020:1 (the “Warrants”). Those who

Offer document regarding Peutinger AB’s mandatory cash offer to the shareholders of Internationella Engelska Skolan i Sverige Holdings II AB (publ) made public

THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS

Record date for distribution of warrants of series TO1 and TO2 to current shareholders is set for October 9, 2020

As previously announced, the Board of Directors of Cereno Scientific AB (”Cereno” or the ”Company”) has decided to distribute warrants of series TO1 and TO2 free of charge to shareholders in the Company. The subscription period to subscribe for new shares of series B with conversion of warrants from series TO1 will be from 15 September 2021 until and including 29 September 2021. The subscription period to subscribe for new shares of series B with conversion of warrants of TO2 will be from 14 September 2022 until and including 28 September 2022.As previously announced through a press release

UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 02.10.2020

United Bankers Corporation NOTIFICATION 02.10.2020 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 02.10.2020 Date 02.10.2020Exchange transaction BuyShare class UNIAVAmount 562Average price/share 9.2000 EURHighest price/share 9.2000 EURLowest price/share 9.2000 EURTotal price 5,170.40 EUR The shares held by United Bankers Corporation on 02.10.2020: UNIAV 19,769   On behalf of United Bankers Corporation  Skandinaviska Enskilda Banken AB (Publ) Antti

Cantargia reports first patient treated with CAN04 in a US phase I study investigating combination with pembrolizumab

Cantargia AB today announced that the first patient has started treatment with the antibody CAN04 and pembrolizumab in a phase I clinical trial in USA. The trial continues according to the clinical protocol and will include up to 18 patients.Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and blockade of IL-1 signaling. A new phase Ib clinical trial investigates CAN04 in combination with pembrolizumab which

An Advocacy Toolkit for Nature: Biodiversity loss, nature protection, and the EU strategy for nature

Nature matters, because…  · Biodiversity underpins all life on Earth  · Losing biodiversity means losing the vital services that societies depend on  · Ecosystems and soils absorb carbon and help us limit the effects of climate change  The Advocacy Toolkit for Nature, published under the EU Biodiversity Strategy for 2030, offers an overall understanding of biodiversity loss and its effects in nature, the reasons behind it and the link with climate change.  Read the Advocacy toolkit in 25 languages.

Board Member Artur Aira is taking the position as Bioprinting Business Area Manager

Artur Aira, who holds a master’s degree in medical technology engineering and an MBA, is leaving the CELLINK Board of Directors for an operational role as Business Area Manager for the bioprinting business unit. Artur has a wealth of experience within the life sciences industry, has served as CEO Abigo medical, Executive Vice President at AddLife, and has held various leadership roles at Organon Teknika, bioMerieux and AddTech Life Science. With over 30 years’ experience, he is an authority on setting up organizations in the pharmaceutical and diagnostics industries to achieve impressive

HANZA invites to Q3 2020 presentation on November 3 at 11.oo am

HANZA Holding AB (publ), will publish its interim report for the third quarter of 2020 on Tuesday November 3, at 8.00 am CET. In connection with the report, HANZA invites investors, shareholders and journalists to a combined audiocast and conference call at 11.00 am CET the same day.The report will be presented by Erik Stenfors, CEO, and Lars Åkerblom, CFO.The presentation will be held in English.  Link to webcast:https://tv.streamfabriken.com/hanza-q3-2020  Dial in numbers for the conference call: Sweden: +46 8 566 427 03United Kingdom: +44 333 300 92 62USA: +1 833 249

#20-352 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

DanCann Pharma A/S: DanCann Pharma A/S receives approval for listing and publishes prospectus

Today, DanCann Pharma A/S ("DanCann Pharma" or “the Company”) announces that the Company has received approval for listing at Spotlight Stock Market. The approval is given under the condition that the Company raises the minimum limit and that the company obtains a sufficient number of shareholders in accordance with Spotlight Stock Market’s listing agreement in the upcoming IPO. DanCann Pharma today also publishes the prospectus for the upcoming issue of units, for which the subscription period starts on Wednesday, the 7[th] of October 2020, and ends on the 23[rd] of October 2020. The

Renewcell establishes textile recycling at SCA’s industrial site Ortviken

SCA and the textile recycling company Renewcell have signed an agreement for Renewcell to establish textile recycling at SCA’s industrial site Ortviken in Sundsvall. The operation is expected to create one hundred new jobs.“We are glad that Renewcell chooses Ortviken as the site for this investment”, says Ulf Larsson, SCA’s President. “We know that Ortviken is a very attractive industrial site with excellent infrastructure, including first class logistic solutions.” SCA will discontinue the production of publication paper at Ortviken and will thereafter make room for Renewcell’s

Omnicar Holding AB: update on our financial situation and a directed share issue

Omnicar Holding AB is pleased to announce that Omnicar Holding AB successfully have repaid and settled most of our external debt during the recent few months.The final external debt will be settled with below directed share issue. Claus T. Hansen “We now have a solid foundation for our future growth and an improved financial security and stability. Only debt obligation left in the company is the bridge loan I have with the company. I have agreed to extend the loan to a new period of 6 month” New directed issue Unwrap Finance Nordic AB have undertaken to subscribe to 3.748.000

Change in number of shares and votes in Lindab

The number of shares and votes in Lindab International AB (publ) has changed as a result of the issue of 25,000 new shares in September, upon exercise of warrants in the incentive programme adopted by the shareholders’ meeting held 9 May 2017. Subsequent to the exercise of warrants, the total number of shares in Lindab as of 30 September 2020 was 78,732,820 and the total number of votes was 78,732,820. The total number of outstanding shares as of 30 September 2020 is 76,356,982 as Lindab has 2,375,838 shares in its possession. Contact Ola RanstamGeneral Counsel (Interim)E-mail:

Correction to Nurminen Logistics Plc’s Stock Exchange Release published on October 1, 2020, related to the number of shares held by the company

Nurminen Logistics Plc                    Stock Exchange Release 2 October 2020, at 4.00 p.m   The Stock Exchange Release published by Nurminen Logistics Plc on 1 October 2020 incorrectly stated that the number of shares held by the company was 249,872. The correct number of shares held by the company after the registration of the new shares is 208,801 shares, of which 143,539 shares will be transferred to the members of the Board of Directors as annual remuneration on or about October 7, 2020. After the transfer, the number of shares held by the Company is 65,262. Nurminen

Relais Group Plc - Managers' Transactions

Relais Group Plc, Stock Exchange Release, 2 October 2020 at 3:35 P.M.Person subject to the notification requirement Name: Salmivuori Ari Position: Closely associated person Issuer: Relais Group Oyj LEI: 743700X9S8FVYRI20J88 Notification type: INITIAL NOTIFICATION Reference number: 743700X9S8FVYRI20J88_20201002132156_5 ____________________________________________ Transaction date: 2020-09-30 Venue not applicable Instrument type: SHARE ISIN: FI4000391487 Nature of the transaction: EXERCISE (RIGHTS, PUT AND CALL OPTIONS) Transaction details (1): Volume:

Relais Group Plc - Managers' Transactions

Relais Group Plc, Stock Exchange Release, 2 October 2020 at 3:35 P.M.Person subject to the notification requirement Name: Salmivuori AriPosition: Closely associated person Issuer: Relais Group Oyj LEI: 743700X9S8FVYRI20J88 Notification type: INITIAL NOTIFICATION Reference number: 743700X9S8FVYRI20J88_20201002141025_3 ____________________________________________ Transaction date: 2020-09-30 Venue not applicable Instrument type: SHARE ISIN: FI4000391487 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 221,625 Unit price: 8.36 EUR

Relais Group Plc - Managers' Transactions

Relais Group Plc, Stock Exchange Release, 2 October 2020 at 3.35 P.M.Person subject to the notification requirement Name: Nordic Industry Development ABPosition: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Jesper Otterbeck Position: Member of the Board Issuer: Relais Group Plc LEI: 743700X9S8FVYRI20J88 Notification type: INITIAL NOTIFICATION Reference number: 743700X9S8FVYRI20J88_20201002130739_3 ____________________________________________ Transaction date: 30.9.2020 Venue not applicable

There are no items matching the current filter
There are no more items matching the current filter
Back to top